Your session is about to expire
← Back to Search
Exendin-9,39 for Type 2 Diabetes
Study Summary
This trial will test whether GLP-1, a hormone made by the body, can help people with type 2 diabetes produce insulin.
- Type 2 Diabetes
- Healthy Subjects
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research include elderly patients who are over the age of 75?
"The age limit for this clinical trial is 65 years old. Any patients that are over 25 and younger than the age limit are eligible to enroll."
Exendin-9,39 is most commonly associated with which treatments?
"Exendin-9,39 is frequently given to patients suffering from ascorbic acid deficiency. However, this medication can also be taken to treat conditions related to medical devices, sprains, and unstable angina pectoris."
Have similar medical trials been conducted before?
"Since its first study in 2006, Exendin-9,39 has undergone extensive clinical research with 60 active trials today. These trials are conducted in 220 cities across 23 countries and have involved415 people total."
Is Exendin-9,39 dangerous for human beings?
"Exendin-9,39 is a medication that has undergone Phase 3 clinical trials. This signifies that, while there is data affirming its efficacy, multiple rounds of testing have also backed up its safety. Our team rates its safety as a 3."
Are there any other peer-reviewed papers that mention Exendin-9,39?
"There are a total of 60 ongoing studies regarding Exendin-9,39. Of these, 18 are in Phase 3. Most trials for Exendin-9,39 are located in Nieuwegein and Utrecht, but there are a total of 420 medical centres running trials for this medication."
Share this study with friends
Copy Link
Messenger